Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10148MR)

This product GTTS-WQ10148MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10148MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ6218MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ754MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ877MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ1720MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ10210MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ7167MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ8244MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW